Male Androgenic Alopecia (Pattern Baldness) Protocol
Male Androgenic Alopecia (Pattern Baldness) Protocol framework focused on consistent execution, practical monitoring, and safer progression.
A peptide protocol targeting the multifactorial mechanisms of male pattern baldness—follicular miniaturization, scalp microinflammation, reduced dermal papilla vascularization, and declining follicular stem cell activity.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Male Androgenic Alopecia (Pattern Baldness) Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Minimum 6 months to assess hair cycle response; ongoing maintenance thereafter
Target Audience
Men with Norwood scale II-VI androgenic alopecia seeking peptide adjunct to standard therapy (finasteride, minoxidil)
| Compound | Dose | Frequency |
|---|---|---|
| GHK-Cu Direct keratinocyte and dermal papilla cell stimulation | 2 mg | Daily (topical or SC) |
| GHK Follicular matrix remodeling and fibroblast activation | 1 mg | Daily (topical preferred) |
| Melanotan 1 MC1R activation for follicular cycling and papilla stimulation | 0.5 mg | Three times weekly |
| TB-500 Dermal papilla microvasculature angiogenesis | 5 mg | Twice weekly |
| BPC-157 Scalp inflammation reduction and follicular microenvironment repair | 250 mcg | Daily |
Free Peptide Guide
Male Androgenic Alopecia (Pattern Baldness) Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned GHK-Cu timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Male Androgenic Alopecia (Pattern Baldness) Protocol run before reassessment?
A common window is Minimum 6 months to assess hair cycle response; ongoing maintenance thereafter, with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with GHK-Cu + GHK execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
GHK-Cu is the most evidence-backed compound for hair growth, directly stimulating keratinocyte proliferation, increasing follicular cell division, and upregulating the expression of hair growth genes in dermal papilla cells. GHK (plain) supports dermal matrix remodeling and fibroblast function in the follicular environment. Melanotan I activates MC1R on dermal papilla cells, stimulating follicular cycling and pigmentation recovery. TB-500 promotes angiogenesis in the dermal papilla microcirculation essential for active follicles. BPC-157 reduces the scalp inflammation and reactive oxygen species that drive progressive follicular miniaturization.
Clinical Research
No clinical references were provided for this stack yet.
More Skin & Cosmetic Stacks
Advanced Cosmetic Anti-Aging Topical Stack
Comprehensive topical peptide system targeting expression lines, skin laxity, collagen degradation, and oxidative damage. Suitable for daily facial and neck application.
Advanced Skin Rejuvenation & Anti-Aging Cosmetic Protocol
Comprehensive cosmetic peptide protocol targeting collagen synthesis, wrinkle reduction, skin elasticity, hyperpigmentation, and epidermal regeneration for clinically significant anti-aging skin improvement.
Comprehensive Anti-Aging Skincare Stack
A complete multi-peptide topical skincare system targeting all major aging mechanisms: collagen loss, expression lines, photo-aging, inflammation, and loss of skin firmness for comprehensive facial rejuvenation.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Male Androgenic Alopecia (Pattern Baldness) Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.